| Autor: |
Bil JP; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands., Schrooders PA; Department of Infectious Diseases, Public Health Service of Noord- en Oost-Gelderland, Warnsveld, the Netherlands., Prins M; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.; Department of Internal Medicine, Amsterdam Infection and Immunity Institute (AI&II), Academic Medical Center (University of Amsterdam), Amsterdam, The Netherlands., Kouw PM; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands., Klomp JH; Department of Infectious Diseases, Public Health Service of Gelderland Zuid, Nijmegen, the Netherlands., Scholing M; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.; Department of Medical Microbiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, the Netherlands., Huijbregts LP; Department of Infectious Diseases, Public Health Service of Noord- en Oost-Gelderland, Warnsveld, the Netherlands., Sonder GJ; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.; Department of Internal Medicine, Amsterdam Infection and Immunity Institute (AI&II), Academic Medical Center (University of Amsterdam), Amsterdam, The Netherlands., Waegemaekers TC; National Coordination Centre for Communicable Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands., de Vries HJ; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.; Department of Internal Medicine, Amsterdam Infection and Immunity Institute (AI&II), Academic Medical Center (University of Amsterdam), Amsterdam, The Netherlands., Meijer W; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands., Zuure FR; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.; Department of Internal Medicine, Amsterdam Infection and Immunity Institute (AI&II), Academic Medical Center (University of Amsterdam), Amsterdam, The Netherlands.; These authors share joint last authorship., Tostmann A; These authors share joint last authorship.; Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, the Netherlands. |
| Abstrakt: |
We evaluated uptake and diagnostic outcomes of voluntary hepatitis B (HBV) and C virus (HCV) screening offered during routine tuberculosis entry screening to migrants in Gelderland and Amsterdam, the Netherlands, between 2013 and 2015. In Amsterdam, HIV screening was also offered. Overall, 54% (461/859) accepted screening. Prevalence of chronic HBV infection (HBsAg-positive) and HCV exposure (anti-HCV-positive) in Gelderland was 4.48% (9/201; 95% confidence interval (CI): 2.37-8.29) and 0.99% (2/203; 95% CI: 0.27-3.52), respectively, all infections were newly diagnosed. Prevalence of chronic HBV infection, HCV exposure and chronic HCV infection (HCV RNA-positive) in Amsterdam was 0.39% (1/256; 95% CI: 0.07-2.18), 1.17% (3/256; 95% CI: 0.40-3.39) and 0.39% (1/256; 95% CI: 0.07-2.18), respectively, with all chronic HBV/HCV infections previously diagnosed. No HIV infections were found. In univariate analyses, newly diagnosed chronic HBV infection was more likely in participants migrating for reasons other than work or study (4.35% vs 0.83%; odds ratio (OR) = 5.45; 95% CI: 1.12-26.60) and was less likely in participants in Amsterdam than Gelderland (0.00% vs 4.48%; OR = 0.04; 95% CI: 0.00-0.69). Regional differences in HBV prevalence might be explained by differences in the populations entering compulsory tuberculosis screening. Prescreening selection of migrants based on risk factors merits further exploration. |
